Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1990 Nov;58(11):3653–3662. doi: 10.1128/iai.58.11.3653-3662.1990

Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccine.

S M Loosmore 1, G R Zealey 1, H A Boux 1, S A Cockle 1, K Radika 1, R E Fahim 1, G J Zobrist 1, R K Yacoob 1, P C Chong 1, F L Yao 1, et al.
PMCID: PMC313711  PMID: 2228237

Abstract

Pertussis toxin (PT) is an important protective antigen in vaccines against whooping cough, and a genetically detoxified PT analog is the preferred form of the immunogen. Several amino acids of the S1 subunit were identified as functionally critical residues by site-directed mutagenesis, specifically, those at positions 9, 13, 26, 35, 41, 58, and 129. Eighty-three mutated PT operons were introduced into Bordetella parapertussis, and the resultant toxin analogs were screened for expression levels, enzymatic activity, residual toxicity, and antigenicity. While more than half of the mutants were found to be poorly secreted or assembled, the rest were fully assembled and most were highly detoxified. Single mutations resulted in up to a 1,000-fold reduction in both toxic and enzymatic activities, while PT analogs with multiple mutations (Lys-9 Gly-129, Glu-58 Gly-129, and Lys-9 Glu-58 Gly-129) were 10(6)-fold detoxified. Operons coding for stable and nontoxic mutants shown to express a critical immunodominant protective epitope were returned to the chromosome of Bordetella pertussis by allelic exchange. In vivo analysis of the toxin analogs showed a dramatic reduction in histamine sensitization and lymphocytosis-promoting activities, paralleling the reduction in toxic activities. All mutants were protective in an intracerebral challenge test, and the Lys-9 Gly-129 analog was found to be significantly more immunogenic than the toxoid. PT analogs such as those described represent suitable components for the design of a recombinant whooping cough vaccine.

Full text

PDF
3653

Images in this article

3658Image
on p.3658
3658Image
on p.3658

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Askelöf P., Gillenius P. Effect of lymphocytosis-promoting factor from Bordetella pertussis on cerebellar cyclic GMP levels. Infect Immun. 1982 Jun;36(3):958–961. doi: 10.1128/iai.36.3.958-961.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barbieri J. T., Collier R. J. Expression of a mutant, full-length form of diphtheria toxin in Escherichia coli. Infect Immun. 1987 Jul;55(7):1647–1651. doi: 10.1128/iai.55.7.1647-1651.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barbieri J. T., Cortina G. ADP-ribosyltransferase mutations in the catalytic S-1 subunit of pertussis toxin. Infect Immun. 1988 Aug;56(8):1934–1941. doi: 10.1128/iai.56.8.1934-1941.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barbieri J. T., Mende-Mueller L. M., Rappuoli R., Collier R. J. Photolabeling of Glu-129 of the S-1 subunit of pertussis toxin with NAD. Infect Immun. 1989 Nov;57(11):3549–3554. doi: 10.1128/iai.57.11.3549-3554.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bartley T. D., Whiteley D. W., Mar V. L., Burns D. L., Burnette W. N. Pertussis holotoxoid formed in vitro with a genetically deactivated S1 subunit. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8353–8357. doi: 10.1073/pnas.86.21.8353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bradley D. E., Taylor D. E., Cohen D. R. Specification of surface mating systems among conjugative drug resistance plasmids in Escherichia coli K-12. J Bacteriol. 1980 Sep;143(3):1466–1470. doi: 10.1128/jb.143.3.1466-1470.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brandhuber B. J., Allured V. S., Falbel T. G., McKay D. B. Mapping the enzymatic active site of Pseudomonas aeruginosa exotoxin A. Proteins. 1988;3(3):146–154. doi: 10.1002/prot.340030303. [DOI] [PubMed] [Google Scholar]
  8. Burnette W. N., Cieplak W., Mar V. L., Kaljot K. T., Sato H., Keith J. M. Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope. Science. 1988 Oct 7;242(4875):72–74. doi: 10.1126/science.2459776. [DOI] [PubMed] [Google Scholar]
  9. Burns D. L., Kenimer J. G., Manclark C. R. Role of the A subunit of pertussis toxin in alteration of Chinese hamster ovary cell morphology. Infect Immun. 1987 Jan;55(1):24–28. doi: 10.1128/iai.55.1.24-28.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Burns D. L., Manclark C. R. Role of cysteine 41 of the A subunit of pertussis toxin. J Biol Chem. 1989 Jan 5;264(1):564–568. [PubMed] [Google Scholar]
  11. Burstyn D. G., Baraff L. J., Peppler M. S., Leake R. D., St Geme J., Jr, Manclark C. R. Serological response to filamentous hemagglutinin and lymphocytosis-promoting toxin of Bordetella pertussis. Infect Immun. 1983 Sep;41(3):1150–1156. doi: 10.1128/iai.41.3.1150-1156.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Cieplak W., Burnette W. N., Mar V. L., Kaljot K. T., Morris C. F., Chen K. K., Sato H., Keith J. M. Identification of a region in the S1 subunit of pertussis toxin that is required for enzymatic activity and that contributes to the formation of a neutralizing antigenic determinant. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4667–4671. doi: 10.1073/pnas.85.13.4667. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cockle S. A. Identification of an active-site residue in subunit S1 of pertussis toxin by photocrosslinking to NAD. FEBS Lett. 1989 Jun 5;249(2):329–332. doi: 10.1016/0014-5793(89)80652-0. [DOI] [PubMed] [Google Scholar]
  14. Ditta G., Schmidhauser T., Yakobson E., Lu P., Liang X. W., Finlay D. R., Guiney D., Helinski D. R. Plasmids related to the broad host range vector, pRK290, useful for gene cloning and for monitoring gene expression. Plasmid. 1985 Mar;13(2):149–153. doi: 10.1016/0147-619x(85)90068-x. [DOI] [PubMed] [Google Scholar]
  15. Douglas C. M., Collier R. J. Exotoxin A of Pseudomonas aeruginosa: substitution of glutamic acid 553 with aspartic acid drastically reduces toxicity and enzymatic activity. J Bacteriol. 1987 Nov;169(11):4967–4971. doi: 10.1128/jb.169.11.4967-4971.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fawzi A. B., Northup J. K. Guanine nucleotide binding characteristics of transducin: essential role of rhodopsin for rapid exchange of guanine nucleotides. Biochemistry. 1990 Apr 17;29(15):3804–3812. doi: 10.1021/bi00467a030. [DOI] [PubMed] [Google Scholar]
  17. Granström M., Granström G., Gillenius P., Askelöf P. Neutralizing antibodies to pertussis toxin in whooping cough. J Infect Dis. 1985 Apr;151(4):646–649. doi: 10.1093/infdis/151.4.646. [DOI] [PubMed] [Google Scholar]
  18. Imaizumi A., Suzuki Y., Ono S., Sato H., Sato Y. Effect of heptakis (2,6-O-dimethyl) beta-cyclodextrin on the production of pertussis toxin by Bordetella pertussis. Infect Immun. 1983 Sep;41(3):1138–1143. doi: 10.1128/iai.41.3.1138-1143.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kaslow H. R., Schlotterbeck J. D., Mar V. L., Burnette W. N. Alkylation of cysteine 41, but not cysteine 200, decreases the ADP-ribosyltransferase activity of the S1 subunit of pertussis toxin. J Biol Chem. 1989 Apr 15;264(11):6386–6390. [PubMed] [Google Scholar]
  20. Kendrick P. L., Eldering G., Dixon M. K., Misner J. Mouse Protection Tests in the Study of Pertussis Vaccine: A Comparative Series Using the Intracerebral Route for Challenge. Am J Public Health Nations Health. 1947 Jul;37(7):803–810. [PMC free article] [PubMed] [Google Scholar]
  21. Kenimer J. G., Kim K. J., Probst P. G., Manclark C. R., Burstyn D. G., Cowell J. L. Monoclonal antibodies to pertussis toxin: utilization as probes of toxin function. Hybridoma. 1989 Feb;8(1):37–51. doi: 10.1089/hyb.1989.8.37. [DOI] [PubMed] [Google Scholar]
  22. Locht C., Barstad P. A., Coligan J. E., Mayer L., Munoz J. J., Smith S. G., Keith J. M. Molecular cloning of pertussis toxin genes. Nucleic Acids Res. 1986 Apr 25;14(8):3251–3261. doi: 10.1093/nar/14.8.3251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Locht C., Capiau C., Feron C. Identification of amino acid residues essential for the enzymatic activities of pertussis toxin. Proc Natl Acad Sci U S A. 1989 May;86(9):3075–3079. doi: 10.1073/pnas.86.9.3075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Locht C., Keith J. M. Pertussis toxin gene: nucleotide sequence and genetic organization. Science. 1986 Jun 6;232(4755):1258–1264. doi: 10.1126/science.3704651. [DOI] [PubMed] [Google Scholar]
  25. Loosmore S. M., Cunningham J. D., Bradley W. R., Yao F. L., Dekaban G. A., Klein M. H. A unique sequence of the Bordetella pertussis toxin operon. Nucleic Acids Res. 1989 Oct 25;17(20):8365–8365. doi: 10.1093/nar/17.20.8365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lukac M., Pier G. B., Collier R. J. Toxoid of Pseudomonas aeruginosa exotoxin A generated by deletion of an active-site residue. Infect Immun. 1988 Dec;56(12):3095–3098. doi: 10.1128/iai.56.12.3095-3098.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Manning D. R., Fraser B. A., Kahn R. A., Gilman A. G. ADP-ribosylation of transducin by islet-activation protein. Identification of asparagine as the site of ADP-ribosylation. J Biol Chem. 1984 Jan 25;259(2):749–756. [PubMed] [Google Scholar]
  28. Marwick C. Pertussis vaccines: trials (and tribulations) JAMA. 1988 Apr 8;259(14):2057–2059. [PubMed] [Google Scholar]
  29. Moss J., Stanley S. J., Burns D. L., Hsia J. A., Yost D. A., Myers G. A., Hewlett E. L. Activation by thiol of the latent NAD glycohydrolase and ADP-ribosyltransferase activities of Bordetella pertussis toxin (islet-activating protein). J Biol Chem. 1983 Oct 10;258(19):11879–11882. [PubMed] [Google Scholar]
  30. Munoz J. J., Arai H., Bergman R. K., Sadowski P. L. Biological activities of crystalline pertussigen from Bordetella pertussis. Infect Immun. 1981 Sep;33(3):820–826. doi: 10.1128/iai.33.3.820-826.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Nencioni L., Pizza M., Bugnoli M., De Magistris T., Di Tommaso A., Giovannoni F., Manetti R., Marsili I., Matteucci G., Nucci D. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough. Infect Immun. 1990 May;58(5):1308–1315. doi: 10.1128/iai.58.5.1308-1315.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Nicosia A., Perugini M., Franzini C., Casagli M. C., Borri M. G., Antoni G., Almoni M., Neri P., Ratti G., Rappuoli R. Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication. Proc Natl Acad Sci U S A. 1986 Jul;83(13):4631–4635. doi: 10.1073/pnas.83.13.4631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nogimori K., Tamura M., Yajima M., Ito K., Nakamura T., Kajikawa N., Maruyama Y., Ui M. Dual mechanisms involved in development of diverse biological activities of islet-activating protein, pertussis toxin, as revealed by chemical modification of lysine residues in the toxin molecule. Biochim Biophys Acta. 1984 Sep 28;801(2):232–243. doi: 10.1016/0304-4165(84)90072-2. [DOI] [PubMed] [Google Scholar]
  34. Papini E., Schiavo G., Sandoná D., Rappuoli R., Montecucco C. Histidine 21 is at the NAD+ binding site of diphtheria toxin. J Biol Chem. 1989 Jul 25;264(21):12385–12388. [PubMed] [Google Scholar]
  35. Pizza M., Bartoloni A., Prugnola A., Silvestri S., Rappuoli R. Subunit S1 of pertussis toxin: mapping of the regions essential for ADP-ribosyltransferase activity. Proc Natl Acad Sci U S A. 1988 Oct;85(20):7521–7525. doi: 10.1073/pnas.85.20.7521. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Pizza M., Covacci A., Bartoloni A., Perugini M., Nencioni L., De Magistris M. T., Villa L., Nucci D., Manetti R., Bugnoli M. Mutants of pertussis toxin suitable for vaccine development. Science. 1989 Oct 27;246(4929):497–500. doi: 10.1126/science.2683073. [DOI] [PubMed] [Google Scholar]
  37. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Sayers J. R., Schmidt W., Eckstein F. 5'-3' exonucleases in phosphorothioate-based oligonucleotide-directed mutagenesis. Nucleic Acids Res. 1988 Feb 11;16(3):791–802. doi: 10.1093/nar/16.3.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Stainer D. W., Scholte M. J. A simple chemically defined medium for the production of phase I Bordetella pertussis. J Gen Microbiol. 1970 Oct;63(2):211–220. doi: 10.1099/00221287-63-2-211. [DOI] [PubMed] [Google Scholar]
  40. Tamura M., Nogimori K., Murai S., Yajima M., Ito K., Katada T., Ui M., Ishii S. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry. 1982 Oct 26;21(22):5516–5522. doi: 10.1021/bi00265a021. [DOI] [PubMed] [Google Scholar]
  41. Tweten R. K., Barbieri J. T., Collier R. J. Diphtheria toxin. Effect of substituting aspartic acid for glutamic acid 148 on ADP-ribosyltransferase activity. J Biol Chem. 1985 Sep 5;260(19):10392–10394. [PubMed] [Google Scholar]
  42. Watkins P. A., Burns D. L., Kanaho Y., Liu T. Y., Hewlett E. L., Moss J. ADP-ribosylation of transducin by pertussis toxin. J Biol Chem. 1985 Nov 5;260(25):13478–13482. [PubMed] [Google Scholar]
  43. Yacoob R. K., Zealey G. R. A one-step procedure for the purification of high molecular weight bacterial chromosomal DNA. Nucleic Acids Res. 1988 Feb 25;16(4):1639–1639. doi: 10.1093/nar/16.4.1639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Yajima M., Hosoda K., Kanbayashi Y., Nakamura T., Nogimori K., Mizushima Y., Nakase Y., Ui M. Islets-activating protein (IAP) in Bordetella pertussis that potentiates insulin secretory responses of rats. Purification and characterization. J Biochem. 1978 Jan;83(1):295–303. doi: 10.1093/oxfordjournals.jbchem.a131904. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES